Concise review: Maturation phases of human pluripotent stem cell-derived cardiomyocytes

Stem Cells

Volumn 31, Issue 5, 2013, Pages 829-837

  Robertson, Claire ^a,b   Tran, David D ^a,b   George, Steven C ^a,b,c  

^a University of California at Irvine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiomyocyte; In vitro cell culture; Maturity; Phenotype; Pluripotent stem cells

Indexed keywords

CALCIUM CHANNEL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ACTION POTENTIAL; APOPTOSIS; BIOENERGY; CALCIUM CELL LEVEL; CELL DAMAGE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL MEMBRANE DEPOLARIZATION; CELL METABOLISM; CELL PROLIFERATION; CELL STRUCTURE; CHRONOTROPISM; ELECTROPHYSIOLOGY; GENE EXPRESSION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; INOTROPISM; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; POTASSIUM CURRENT; PROTEIN EXPRESSION; REVIEW;

CELL DIFFERENTIATION; HUMANS; MYOCYTES, CARDIAC; PLURIPOTENT STEM CELLS;

EID: 84876570848     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1331     Document Type: Review

References (141)

1. Roger VL, Go AS, Lloyd-Jones D et al. AHA statistical update heart disease and stroke statistics - 2012 update. A report from the American Heart Association. Circulation 2012;125:e2-e220.
2. Bruneau BG. The developmental genetics of congenital heart disease. Nature 2008;451:943-948. (Pubitemid 351301750)
3. Lipshultz SE, Sleeper LA, Towbin JA et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003;348:1647-1655. (Pubitemid 36459470)
4. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ 2005;172:765-767. (Pubitemid 40388735)
5. Denning C, Anderson D. Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. Drug Discov Today Ther Strateg 2008;5:223-232.
6. Mandenius CF, Steel D, Noor F et al. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-theart bioanalytics: A review. J Appl Toxicol 2011;31(3):191-205.
7. Snir M, Kehat I, Gepstein A et al. Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. Am J Physiol Heart Circ Physiol 2003;285:H2355-H2363. (Pubitemid 37443051)
8. Dick E, Rajamohan D, Ronksley J et al. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans 2010;38(4):1037-1045.
9. Faustino RS, Chiriac A, Niederlander NJ et al. Decoded calreticulin-deficient embryonic stem cell transcriptome resolves latent cardiophenotype. Stem Cells 2010;28(7):1281-1291.
10. Otsuji TG, Minami I, Kurose Y et al. Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs. Stem Cell Res 2010;4(3):201-213.
11. Yazawa M, Hsueh B, Jia X et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011;471(7337):230- 234.
12. Lahti AL, Kujala VJ, Chapman H et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 2012;5(2):220-230.
13. Itzhaki I, Maizels L, Huber I et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471(7337):225-229.
14. Jung CB, Moretti A, Mederos y Schnitzler M et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 2012;4(3):180-191.
15. Caspi O, Gepstein L. Regenerating the heart using human embryonic stem cells - From cell to bedside. Isr Med Assoc J 2006;8(3):208-214.
16. Liu J, Zhang Z, Liu Y et al. Generation, characterization, and potential therapeutic applications of cardiomyocytes from various stem cells. Stem Cells Dev 2012;21(12):2095-2110.
17. Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev 2010;6(1):108-120.
18. Xu C, Police S, Rao N et al. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res 2002;91(6):501-508.
19. Rose RA, Jiang H, Wang X et al. Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells 2008;26(11):2884-2892.
20. Rangappa S, Fen C, Lee EH et al. Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann Thorac Surg 2003;75(3):775-779. (Pubitemid 36298339)
21. Heubach JF, Graf EM, Leutheuser J et al. Electrophysiological properties of human mesenchymal stem cells. J Physiol 2004;554(Pt 3):659-672. (Pubitemid 38219882)
22. Fukuda K. Reprogramming of bone marrow mesenchymal stem cells into cardiomyocytes. C R Biol 2002;325(10):1027-1038. (Pubitemid 35446566)
23. Sachinidis A, Fleischmann BK, Kolossov E et al. Cardiac specific differentiation of mouse embryonic stem cells. Cardiovasc Res 2003;58(2):278-291. (Pubitemid 36570387)
24. Smith AG. Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol 2001;17:435-462. (Pubitemid 33096183)
25. Mummery C, Ward D, van den Brink CE et al. Cardiomyocyte differentiation of mouse and human embryonic stem cells. J Anat 2002;200(Pt 3):233-242. (Pubitemid 34467315)
26. Boheler KR, Czyz J, Tweedie D et al. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ Res 2002;91(3):189-201. (Pubitemid 34875673)
27. Mummery CL, Zhang J, Ng ES et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: A methods overview. Circ Res 2012;111(3):344-358.
28. Jiang J, Han P, Zhang Q et al. Cardiac differentiation of human pluripotent stem cells. J Cell Mol Med 2012;16(8):1663-1668.
29. David R, Franz WM. From pluripotency to distinct cardiomyocyte subtypes. Physiology (Bethesda) 2012;27(3):119-129.
30. Habib M, Caspi O, Gepstein L. Human embryonic stem cells for cardiomyogenesis. J Mol Cell Cardiol 2008;45(4):462-474.
31. Blazeski A, Zhu R, Hunter DW et al. Electrophysiological and contractile function of cardiomyocytes derived from human embryonic stem cells. Prog Biophys Mol Biol 2012;110(2):178-195.
32. Barile L, Chimenti I, Gaetani R et al. Cardiac stem cells: Isolation, expansion and experimental use for myocardial regeneration. Nat Clin Pract Cardiovasc Med 2007;4(Suppl 1):S9-S14. (Pubitemid 46151900)
33. Gherghiceanu M, Barad L, Novak A et al. Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: Comparative ultrastructure. J Cell Mol Med 2011;15(11):2539-2551.
34. Yokoo N, Baba S, Kaichi S et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun 2009;387:482-488.
35. Zhang J, Wilson GF, Soerens AG et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009;104(3):e30-e41.
36. Sartiani L, Bochet P, Cerbai E et al. Functional expression of the hyperpolarization-activated, non-selective cation current if in immortalized HL-1 cardiomyocytes. J Physiol 2002;545(Pt 1):81-92. (Pubitemid 35386129)
37. Kim C, Majdi M, Xia P et al. Non-cardiomyocytes influence the electrophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation. Stem Cells Dev 2010;19(6):783-795.
38. Bauwens CL, Peerani R, Niebruegge S et al. Control of human embryonic stem cell colony and aggregate size heterogeneity influences differentiation trajectories. Stem Cells 2008;26(9):2300-2310.
39. McDevitt TC, Laflamme MA, Murry CE. Proliferation of cardiomyocytes derived from human embryonic stem cells is mediated via the IGF/PI 3-kinase/Akt signaling pathway. J Mol Cell Cardiol 2005;39(6):865-873. (Pubitemid 41572319)
40. Mummery C, Ward-van Oostwaard D, Doevendans P et al. Differentiation of human embryonic stem cells to cardiomyocytes: Role of coculture with visceral endoderm-like cells. Circulation 2003;107(21):2733-2740. (Pubitemid 36667249)
41. Fijnvandraat AC, van Ginneken AC, de Boer PA et al. Cardiomyocytes derived from embryonic stem cells resemble cardiomyocytes of the embryonic heart tube. Cardiovasc Res 2003;58(2):399-409. (Pubitemid 36570398)
42. Lieu DK, Liu J, Siu CW et al. Absence of transverse tubules contributes to non-uniform Ca(2+) wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. Stem Cells Dev 2009;18(10):1493-1500.
43. Smolich JJ. Ultrastructural and functional features of the developing mammalian heart: A brief overview. Reprod Fertil Dev 1995;7(3):451-461.
44. Gepstein L, Snir M, Kehat I et al. Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. Am J Physiol Heart Circ Physiol 2003;285(6):H2355-H2363. (Pubitemid 37443051)
45. Binah O, Dolnikov K, Sadan O et al. Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes. J Electrocardiol 2007;40(6 Suppl):S192-S196. (Pubitemid 350052075)
46. 2+ handling and the role of sarcoplasmic reticulum in the contraction. Stem Cells 2006;24(2):236-245.
47. 2+ transients and contraction in cardiomyocytes derived from embryonic stem cells. FASEB J 2006;20(1):181-183.
48. Itzhaki I, Schiller J, Beyar R et al. Calcium handling in embryonic stem cell-derived cardiac myocytes: Of mice and men. Ann N Y Acad Sci 2006;1080:207-215. (Pubitemid 44955423)
49. Cui L, Johkura K, Takei S et al. Structural differentiation, proliferation, and association of human embryonic stem cell-derived cardiomyocytes in vitro and in their extracardiac tissues. J Struct Biol 2007;158:307-317. (Pubitemid 46764560)
50. Erokhina IL, Semenova EG, Emel'ianova OI. Human fetal ventricular cardiomyocytes in vitro: Proliferation and differentiation. Tsitologiia 2005;47(3):200-206.
51. Horigome H, Takahashi MI, Asaka M et al. Magnetocardiographic determination of the developmental changes in PQ, Qrs and Qt intervals in the foetus. Acta Paediatr 2000;89(1):64-67. (Pubitemid 30060632)
52. Porrello ER, Mahmoud AI, Simpson E et al. Transient regenerative potential of the neonatal mouse heart. Science 2011;331(6020):1078-1080.
53. Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324(5923):98-102.
54. Cowan CA, Klimanskaya I, McMahon J et al. Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med 2004;350:1353-1356. (Pubitemid 38375373)
55. Horio T, Nishikimi T, Yoshihara F et al. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000;35(1 Pt 1):19-24. (Pubitemid 30054231)
56. Holtwick R, van Eickels M, Skryabin BV et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003;111(9):1399-1407. (Pubitemid 36554711)
57. Tanaka T, Tohyama S, Murata M et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 2009;385(4):497-502.
58. Kehat I, Kenyagin-Karsenti D, Snir M et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001;108(3):407-414. (Pubitemid 32730787)
59. Cao F, Wagner RA, Wilson KD et al. Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One 2008;3(10):e3474.
60. Synnergren J, Adak S, Englund MC et al. Cardiomyogenic gene expression profiling of differentiating human embryonic stem cells. J Biotechnol 2008;134:162-170.
61. Synnergren J, Akesson K, Dahlenborg K et al. Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells. Stem Cells 2008;26(7):1831-1840.
62. Synnergren J, Giesler TL, Adak S et al. Differentiating human embryonic stem cells express a unique housekeeping gene signature. Stem Cells 2007;25(2):473-480. (Pubitemid 46232803)
63. Gupta MK, Illich DJ, Gaarz A et al. Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev Biol 2010;10:98.
64. Xu XQ, Soo SY, Sun W et al. Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells 2009;27:2163-2174.
65. Synnergren J, Heins N, Brolen G et al. Transcriptional profiling of human embryonic stem cells differentiating to definitive and primitive endoderm and further toward the hepatic lineage. Stem Cells Dev 2010;19(7):961-978.
66. Tashiro A, Masuda T, Segawa I. Morphometric comparison of mitochondria and myofibrils of cardiomyocytes between hypertrophic and dilated cardiomyopathies. Virchows Arch A: Pathol Anat Histopathol 1990;416(6):473-478. (Pubitemid 20141926)
67. Barth E, Stammler G, Speiser B et al. Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J Mol Cell Cardiol 1992;24(7):669-681.
68. Hattori F, Chen H, Yamashita H et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods 2011;7(1):61-66.
69. Porter GA Jr, Hom J, Hoffman D et al. Bioenergetics, mitochondria, and cardiac myocyte differentiation. Prog Pediatr Cardiol 2011;31(2):75-81.
70. Awasthi S, Matthews DL, Li RA et al. Label-free identification and characterization of human pluripotent stem cell-derived cardiomyocytes using second harmonic generation (SHG) microscopy. J Biophotonics 2012;5(1):57-66.
71. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115(3):500-508. (Pubitemid 40322219)
72. Harris DA, Das AM. Control of mitochondrial ATP synthesis in the heart. Biochem J 1991;280(Pt 3):561-573.
73. Lopaschuk GD, Collins-Nakai RL, Itoi T. Developmental changes in energy substrate use by the heart. Cardiovasc Res 1992;26(12):1172-1180. (Pubitemid 23010529)
74. Lopaschuk G, Jaswal J. Energy metabolic phenotype of the cardiomyocyte during development, differentiation and postnatal maturation. J Cardiovasc Pharmacol 2010;56(2):130-140.
75. Rana P, Anson B, Engle S et al. Characterization of human induced pluripotent stem cell derived cardiomyocytes: Bioenergetics and utilization in safety screening. Toxicol Sci 2012;130(1):117-131.
76. St John JC, Ramalho-Santos J, Gray HL et al. The expression of mitochondrial DNA transcription factors during early cardiomyocyte in vitro differentiation from human embryonic stem cells. Cloning Stem Cells 2005;7(3):141-153. (Pubitemid 43150270)
77. Chung S, Dzeja PP, Faustino RS et al. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med 2007;4(Suppl 1):S60-S67. (Pubitemid 46151906)
78. Bistola V, Nikolopoulou M, Derventzi A et al. Long-term primary cultures of human adult atrial cardiac myocytes: Cell viability, structural properties and BNP secretion in vitro. Int J Cardiol 2008;131(1):113-122.
79. Mitcheson JS, Hancox JC, Levi AJ. Cultured adult cardiac myocytes: Future applications, culture methods, morphological and electrophysiological properties. Cardiovasc Res 1998;39(2):280-300. (Pubitemid 28346525)
80. Cohen JD, Babiarz JE, Abrams RM et al. Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol Appl Pharmacol 2011;257(1):74-83.
81. Simunek T, Sterba M, Popelova O et al. Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009;61(1):154-171.
82. Andersson H, Steel D, Asp J et al. Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells. J Biotechnol 2010;150(1):175-181.
83. Shinozawa T, Furukawa H, Sato E et al. A novel purification method of murine embryonic stem cell- and human-induced pluripotent stem cell-derived cardiomyocytes by simple manual dissociation. J Biomol Screen 2012;17(5):683-691.
84. Sepac A, Sedlic F, Si-Tayeb K et al. Isoflurane preconditioning elicits competent endogenous mechanisms of protection from oxidative stress in cardiomyocytes derived from human embryonic stem cells. Anesthesiology 2010;113(4):906-916.
85. Kim JH, Oh AY, Choi YM et al. Isoflurane decreases death of human embryonic stem cell-derived, transcriptional marker Nkx2.5(+) cardiac progenitor cells. Acta Anaesthesiol Scand 2011;55(9):1124-1131.
86. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007;59(4):418-458.
87. Sedmera D, Kucera P, Raddatz E. Developmental changes in cardiac recovery from anoxia-reoxygenation. Am J Physiol Regul Integr Comp Physiol 2002;283(2):R379-R388. (Pubitemid 34863886)
88. Kang PM, Haunstetter A, Aoki H et al. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res 2000;87(2):118-125. (Pubitemid 30616907)
89. Norstrom A, Akesson K, Hardarson T et al. Molecular and pharmacological properties of human embryonic stem cell-derived cardiomyocytes. Exp Biol Med 2006;231(11):1753-1762. (Pubitemid 44865994)
90. Brito-Martins M, Harding SE, Ali NN. beta(1)- and beta(2)-adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: Comparison with failing and non-failing adult human heart. Br J Pharmacol 2008;153(4):751-759. (Pubitemid 351271760)
91. Mehta A, Chung YY, Ng A et al. Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. Cardiovasc Res 2011;91(4):577-586.
92. Reppel M, Boettinger C, Hescheler J. Beta-adrenergic and muscarinic modulation of human embryonic stem cell-derived cardiomyocytes. Cell Physiol Biochem 2004;14(4-6):187-196. (Pubitemid 39179186)
93. Zwi L, Caspi O, Arbel G et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 2009;120(15):1513-1523.
94. Zwi L, Caspi O, Arbel G et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Hum Gene Ther 2010;21(15):658-658.
95. Xue T, Cho HC, Akar FG et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: Insights into the development of cell-based pacemakers. Circulation 2005;111(1):11-20. (Pubitemid 40070838)
96. Satin J, Kehat I, Caspi O et al. Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J Physiol 2004;559(Pt 2):479-496. (Pubitemid 39263813)
97. Germanguz I, Sedan O, Zeevi-Levin N et al. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J Cell Mol Med 2011;15(1):38-51.
98. Pillekamp F, Haustein M, Khalil M et al. Contractile properties of early human embryonic stem cell-derived cardiomyocytes: Beta-adrenergic stimulation induces positive chronotropy and lusitropy but not inotropy. Stem Cells Dev 2012;10(21):2111-2121.
99. Burridge PW, Thompson S, Millrod MA et al. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011;6(4):e18293.
100. Xu RH, Chen X, Li DS et al. BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat Biotechnol 2002;20(12):1261-1264. (Pubitemid 35462493)
101. Braam SR, Tertoolen L, van de Stolpe A et al. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res 2010;4(2):107-116.
102. Wang K, Terrenoire C, Sampson KJ et al. Biophysical properties of slow potassium channels in human embryonic stem cell derived cardiomyocytes implicate subunit stoichiometry. J Physiol 2011;589(24):6093-6104.
103. Moretti A, Bellin M, Welling A et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363:1397-1409.
104. Bilic J, Izpisua Belmonte JC. Concise review: Induced pluripotent stem cells versus embryonic stem cells: Close enough or yet too far apart? Stem Cells 2012;30(1):33-41.
105. He JQ, Ma Y, Lee Y et al. Human embryonic stem cells develop into multiple types of cardiac myocytes: Action potential characterization. Circ Res 2003;93(1):32-39. (Pubitemid 36859038)
106. Zhu WZ, Xie Y, Moyes KW et al. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res 2010;107(6):776-786.
107. Moore JC, Fu J, Chan YC et al. Distinct cardiogenic preferences of two human embryonic stem cell (hESC) lines are imprinted in their proteomes in the pluripotent state. Biochem Biophys Res Commun 2008;372(4):553-558.
108. Pekkanen-Mattila M, Chapman H, Kerkela E et al. Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype. Exp Biol Med 2010;235(4):522-530.
109. Drouin E, Lande G, Charpentier F. Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 1998;32(4):1063-1067. (Pubitemid 28459600)
110. Yanagi K, Takano M, Narazaki G et al. Hyperpolarization-activated cyclic nucleotide-gated channels and T-type calcium channels confer automaticity of embryonic stem cell-derived cardiomyocytes. Stem Cells 2007;25(11):2712-2719. (Pubitemid 350127855)
111. Pekkanen-Mattila M, Ojala M, Kerkela E et al. The effect of human and mouse fibroblast feeder cells on cardiac differentiation of human pluripotent stem cells. Stem Cells Int 2012 [Epub ahead of print].
112. Zhang Q, Jiang J, Han P et al. Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. Cell Res 2011;21:579-587.
113. Ma J, Guo L, Fiene SJ et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 2011;301(4):H2006-H2017.
114. Veldkamp MW, Verkerk AO, van Ginneken AC et al. Norepinephrine induces action potential prolongation and early afterdepolarizations in ventricular myocytes isolated from human end-stage failing hearts. Eur Heart J 2001;22(11):955-963. (Pubitemid 32625218)
115. Pekkanen-Mattila M, Kerkela E, Tanskanen JM et al. Substantial variation in the cardiac differentiation of human embryonic stem cell lines derived and propagated under the same conditions - A comparison of multiple cell lines. Ann Med 2009;41(5):360-370.
116. 2+ exchanger is a determinant of excitation-contraction coupling in human embryonic stem cell-derived ventricular cardiomyocytes. Stem Cells Dev 2010;19(6):773-782.
117. Zahanich I, Sirenko SG, Maltseva LA et al. Rhythmic beating of stem cell-derived cardiac cells requires dynamic coupling of electrophysiology and Ca cycling. J Mol Cell Cardiol 2011;50(1):66-76.
118. Caspi O, Itzhaki I, Kehat I et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev 2009;18(1):161-172.
119. Gorelik J, Kadir SHSA, Ali NN et al. Embryonic stem cell-derived cardiomyocytes as a model to study fetal arrhythmia related to maternal disease. J Cell Mol Med 2009;13(9B):3730-3741.
120. Bers DM. Cardiac excitation-contraction coupling. Nature 2002;415(6868):198-205. (Pubitemid 34059525)
121. Satin J, Itzhaki I, Rapoport S et al. Calcium handling in human embryonic stem cell-derived cardiomyocytes. Stem Cells 2008;26:1961-1972.
122. Lee YK, Ng KM, Lai WH et al. Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Rev 2011;7(4):976-986.
123. 2+ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin expression. Am J Physiol Cell Physiol 2009;297(1):C152-C159.
124. Itzhaki I, Rapoport S, Huber I et al. Calcium handling in human induced pluripotent stem cell derived cardiomyocytes. PLoS One 2011;7(4):976-986.
125. Dolnikov K, Shilkrut M, Zeevi-Levin N et al. Functional properties of human embryonic stem cell-derived cardiomyocytes. Ann N Y Acad Sci 2005;1047:66-75. (Pubitemid 41123828)
126. 2+ channel pharmacology between native and stem cell-derived cardiomyocytes. J Pharmacol Exp Ther 2012;341(2):510-517.
127. Zhu WZ, Santana LF, Laflamme MA. Local control of excitationcontraction coupling in human embryonic stem cell-derived cardiomyocytes. PLoS One 2009;4(4):e5407.
128. Xi J, Khalil M, Shishechian N et al. Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J 2010;24(8):2739-2751.
129. Mandel Y, Weissman A, Schick R et al. Human embryonic and induced pluripotent stem cell-derived cardiomyocytes exhibit beat rate variability and power-law behavior. Circulation 2012;125(7):883-893.
130. Matsa E, Denning C. In vitro uses of human pluripotent stem cell-derived cardiomyocytes. J Cardiovasc Transl Res 2012;5(5):581-592.
131. Roderick HL, Bootman MD. Pacemaking, arrhythmias, inotropy and hypertrophy: The many possible facets of IP3 signalling in cardiac myocytes. J Physiol 2007;581(3):883-884. (Pubitemid 46887963)
132. Nakayama H, Bodi I, Maillet M et al. The IP3 receptor regulates cardiac hypertrophy in response to select stimuli. Circ Res 2010;107(5):659-666.
133. Hund TJ, Ziman AP, Lederer WJ et al. The cardiac IP3 receptor: Uncovering the role of "the other" calcium-release channel. J Mol Cell Cardiol 2008;45(2):159-161.
134. Liu J, Fu JD, Siu CW et al. Functional sarcoplasmic reticulum for calcium handling of human embryonic stem cell-derived cardiomyocytes: Insights for driven maturation. Stem Cells 2007;25(12):3038-3044. (Pubitemid 350294429)
135. Lee YK, Ng KM, Chan YC et al. Triiodothyronine promotes cardiac differentiation and maturation of embryonic stem cells via the classical genomic pathway. Mol Endocrinol 2010;24(9):1728-1736.
136. Ng KM, Lee YK, Chan YC et al. Exogenous expression of HIF-1 alpha promotes cardiac differentiation of embryonic stem cells. J Mol Cell Cardiol 2010;48(6):1129-1137.
137. Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. Dordrecht: Kluwer Academic Publishers, 2001.
138. Chaudhary KW, Barrezueta NX, Bauchmann MB et al. Embryonic stem cells in predictive cardiotoxicity: Laser capture microscopy enables assay development. Toxicol Sci 2006;90(1):149-158. (Pubitemid 43264735)
139. Luo W, Grupp IL, Harrer J et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994;75(3):401-409.
140. MacLennan DH, Kranias EG. Phospholamban: A crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003;4(7):566-577. (Pubitemid 36773408)
141. Gyorke I, Hester N, Jones LR et al. The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys J 2004;86(4):2121-2128. (Pubitemid 38524402)